STI-6643

STI-6643 binds to human CD47 with a K_d of 76 nM, with lower affinity for cynomolgus (177 nM) and canine (134 nM) CD47 antigens^[1].
STI-6643 (25 min) binds dose-dependently to human MDA-MB-231 (EC₅₀ ~30.0 µg/mL), human RAJI (EC₅₀ 6.64 µg/mL), canine OSCA-40 (EC₅₀ ~30.0 µg/mL), and canine OSCA-78 (EC₅₀ ~30.0 µg/mL) cancer cells^[1].
STI-6643 (0.09-200 µg/mL; 15 min) dose-dependently blocks the CD47/SIRPα interaction on human CCRF-CEM cells with an IC₅₀ of 3.65 µg/mL, without reaching saturation at concentrations up to 200 µg/mL^[1].
STI-6643 (0.0001-10 µg/mL; 30 min) enhances macrophage-mediated phagocytosis of human RAJI-GFP cells^[1].
STI-6643 (1.5625-50 µg/mL) does not exhibit direct tumor cell killing activity on human CCRF-CEM leukemia cells^[1].
STI-6643 (100 µg/mL; 25 min) exhibits negligible binding to human (EC₅₀ = 11.76 µg/mL) and cynomolgus monkey (EC₅₀ = 20.32 µg/mL) RBCs, with slightly stronger binding to canine RBCs (EC₅₀ = 5.10 µg/mL)^[1].
STI-6643 (0.001-300 µg/mL; 20 h) does not induce hemagglutination of human or cynomolgus monkey RBCs at concentrations up to 300 µg/mL, and exhibits weak, 100-fold less potent hemagglutination activity than Hu5F9 in canine RBCs^[1].
STI-6643 (0.001-100 µg/mL; 3 days) preserves human T cell survival and functionality in a superantigen stimulation assay, with minimal impact on IFN-γ secretion^[1].
STI-6643 (0.001-500 µg/mL; 6 days) preserves the survival of human CD4+, CD8+, CD19+, and CD56+ immune cells^[1].
STI-6643 (2.5-5 ng/mL; 30 min) in combination with Rituximab (HY-P9913) enhances macrophage-mediated phagocytosis of human RAJI-GFP cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.